Primary Ciliary Dyskinesia in Childhood: Study Reveals High Burden of ENT Morbidity

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2025-03-03 15:00 GMT   |   Update On 2025-03-03 15:00 GMT

USA: A recent study has shed light on the progression of otologic and nasal symptoms in children with primary ciliary dyskinesia (PCD), revealing that these complications begin early in life and persist throughout childhood. The study found that children with PCD experience ongoing ear and nasal complications.

"Over a follow-up of 7.6 years, 80% required pressure equalization tubes, while hearing loss affected 68% transiently and persisted in 30% of cases. Nasal congestion was nearly universal, with 87% experiencing sinusitis and 35% undergoing multiple sinus surgeries," the researchers reported in the journal OTO Open. These findings highlight the critical need for continuous ENT care in managing PCD-related complications.

PCD is a rare genetic disorder affecting the function of motile cilia, leading to impaired mucociliary clearance. This dysfunction results in chronic respiratory issues, including persistent nasal congestion, recurrent ear infections, and progressive hearing loss. Although these symptoms are well-documented, their long-term progression and variability among patients have remained areas of active research.

While the progression of pulmonary disease has been well documented in multiple studies, longitudinal changes in otologic and nasal symptoms in patients remain poorly understood. To fill this knowledge gap, Adam J. Kimple, Marsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA, and colleagues aimed to determine the prevalence, age of onset, and age-related patterns of self-reported otologic and sinonasal comorbidities in individuals with PCD.

For this purpose, the researchers conducted a prospective, longitudinal, multicenter observational study over up to 12 years across six PCD centers in North America. The study included participants under 19 years of age with a confirmed diagnosis of PCD established through electron microscopy and/or genetic testing. During each study visit, a standardized medical history questionnaire and physical examination were performed to track the progression of symptoms. Descriptive statistical analyses were conducted for the entire cohort and subgroups classified based on ciliary ultrastructure, providing insights into the variability of otologic and sinonasal manifestations over time.

The study revealed the following findings:

  • One-hundred forty-seven participants were monitored for an average of 7.6 ± 3.2 years.
  • Pressure equalization tubes were placed in 80% of cases.
  • The transient hearing loss affected 68% of participants, while 30% experienced persistent hearing loss.
  • Hearing aids were used by 8% and 27% required speech therapy.
  • Those with inner dynein arm/microtubular disorganization defects received pressure equalization tubes earlier than those with outer dynein arm defects.
  • Chronic nasal congestion was reported in 97% of participants.
  • Sinusitis was observed in 87%, and 35% required more than one sinus surgery.

The researchers identified a high prevalence of persistent otologic and sinonasal complications in children with PCD. Nearly all experienced otitis media and nasal congestion, with early pressure equalization tube placement observed in those with specific ultrastructural defects.

"Emphasizing the need for further study, an international consortium is conducting advanced evaluations to refine diagnostic and management approaches for PCD-related upper airway morbidities," the researchers wrote.

Reference:

Dagher I, Kimple AJ, Ferkol TW, Sagel SD, Dell SD, Milla CE, Li L, Lin FC, Sullivan KM, Zariwala MA, Knowles MR, Rosenfeld M, Leigh MW, Davis SD; Genetic Disorders of Mucociliary Clearance Consortium. Progression of Otologic and Nasal Symptoms in Primary Ciliary Dyskinesia Throughout Childhood. OTO Open. 2025 Feb 21;9(1):e70079. doi: 10.1002/oto2.70079. PMID: 39989621; PMCID: PMC11843728.


Tags:    
Article Source : OTO Open

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News